



PTO/SB/08a (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known	
			Application Number	10/576,568
			Filing Date	January 3, 2007
			First Named Inventor	KNOX, SUSAN J.
			Art Unit	1645
Sheet 1 of 6	Examiner Name			
	Attorney Docket Number	STAN-333		

U.S. PATENT DOCUMENTS						
Examiner Initials ¹	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)				
		US- 6,656,509 B1		04-14-1992		
		US- 5,639,787		06-17-1997		
		US- 5,654,328		08-05-1997		
		US- 5,843,481		12-01-1998		
		US- 20020107225		08-08-2002		
		US- 20030018066		01-23-2003		
		US- 5,104,852		12-02-2003		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/576,568		
		Filing Date	January 3, 2007		
		First Named Inventor	KNOX, SUSAN J.		
		Art Unit	1645		
Sheet	2	of	6	Examiner Name	
				Attorney Docket Number	STAN-333

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BALDEW et al., "Selenium-induced Protection against <i>cis</i> -Diamminedichloroplatinum(II) Nephrotoxicity in Mice and Rats." <u>Cancer Res.</u> , 49(11):3020-3 (1989)	
		BUNTZEL, "Erfahrungen mit Natriumselenit in der Behandlung von akuten und späten Nebenwirkungen der Radiochemotherapie von Kopf-Hals-Karzinomen." <u>Med. Klin.</u> , 3:49-53, 94 Suppl. (1999)	
		CAFFREY et al., "Treatment of human ovarian tumor xenografts with selenite prevents the melphalan-induced development of drug resistance." <u>Cancer Chemother. Pharmacol.</u> 46(1):74-8 (2000)	
		CAFFREY et al., "Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo." <u>Anticancer Res.</u> 18(4C): 3017-20 (1998)	
		CAFFREY et al., "Prevention of the Development of Melphalan Resistance In Vitro by Selenite." <u>Biol. Trace. Elem. Res.</u> 65(3):187-98 (1998)	
		CAFFREY et al., "Sensitivity of melphalan-resistant tumors to selenite in vivo." <u>Cancer Lett.</u> 121(2):177-80 (1997)	
		CLARK et al., "Effects of Selenium Supplementation for Cancer Prevention in Patients with Carcinoma of the Skin." <u>JAMA</u> , 276: 1957-1963 (1996)	
		COMBS et al., "Chemopreventive Agents: Selenium." <u>Pharmacol. Ther.</u> , 79(3): 179-192 (1998)	
		COMBS et al., "Selenium and Cancer Prevention." <u>Antioxidants and Disease Prevention</u> , Ch. 8, 97-113. CRC Press, N.Y. (1997);	
		COOK et al., "Cellular Glutathione and Thiol Measurements from Surgically Resected Human Lung Tumor and Normal Lung Tissue." <u>Cancer Res.</u> 51: 4287-4294 (1991)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/576,568
		Filing Date	January 3, 2007
		First Named Inventor	KNOX, SUSAN J.
		Art Unit	1645
		Examiner Name	
Sheet 3 of 6	Attorney Docket Number	STAN-333	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CORCORAN et al., "Inorganic Selenium Retards Progression of Experimental Hormone Refractory Prostate Cancer." <u>J. Urol.</u> 171: 907-910 (2004).	
		FICO et al., "Differential Effects of Selenium on Normal and Neoplastic Canine Mammary Cells." <u>Cancer Res.</u> 46: 3384-3388 (1986)	
		FLEMING et al., "Molecular Mechanisms of Cancer Prevention by Selenium Compounds." <u>Nut Cancer.</u> 40(1): 42-49 (2001)	
		FRENKEL et al., "A Prevention Strategy for Circumventing Drug Resistance in Cancer Chemotherapy." <u>Curr Pharm.</u> 7(16): 1595-614 (2001)	
		GASPARIAN et al., "Selenium Compounds Inhibit IκB Kinase (IKK) and Nuclear Factor-κB (NF-κB) in Prostate Cancer Cells." <u>Mol Canc Ther</u> 1: 1079-1087 (2002)	
		GHOSE et al., "Enhanced Sensitivity of Human Oral Carcinomas to Induction of Apoptosis by Selenium Compounds: Involvement of Mitogen-activated Protein Kinase and Fas Pathways." <u>Cancer Res.</u> 61: 7479-7487 (2001)	
		GHOSH et al., "Rapid induction of apoptosis in prostate cancer cells by selenium: reversal by metabolites of arachidonate 5-lipoxygenase." <u>Biochem Biophys. Res. Comm.</u> 315: 624-635 (2004)	
		GLEAVE et al., "Progression to Androgen Independence is Delayed by Adjuvant Treatment with Antisense Bcl-2 Oligodeoxynucleotides after Castration in the LNCaP Prostate Tumor Model." <u>Clin. Cancer Res.</u> 5: 2891-8 (1999)	
		GLEAVE et al., "Targeting bcl-2 Gene to Delay Androgen-Independent Progression and Enhance Chemosensitivity in Prostate Cancer Using Antisense bcl-2 Oligodeoxynucleotides." <u>Urology.</u> 54(6A): 36-46 (1999)	
		GREEDER et al., "Factors Influencing the Inhibitory Effect of Selenium on Mice Inoculated with Ehrlich Ascites Tumor Cells." <u>Science.</u> 209: 825-827 (1980)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	10/576,568		
		Filing Date	January 3, 2007		
		First Named Inventor	KNOX, SUSAN J.		
		Art Unit	1645		
Sheet	4	of	6	Examiner Name	
				Attorney Docket Number	STAN-333

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		HUSBECK et al., "Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action." <u>Mol Cancer Ther</u> 5(8): 2078-2085 (2006)	
		HUSBECK et al., "Tumor-Selective Killing by Selenite in Patient-Matched Pairs of Normal and Malignant Prostate Cells." <u>The Prostate</u> 66: 218-225 (2006)	
		HUSBECK et al., "Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing." <u>Free Rad Biol Med.</u> 38: 50-57 (2005)	
		IP, et al., "Current concepts of selenium and mammary tumorigenesis." <u>Cellular and Molecular Biology of Breast Cancer</u> , 479-494. Plenum Press, N.Y. (1997)	
		JIANG et al., "Distinct Effects of Methylseleninic Acid <i>versus</i> Selenite on Apoptosis, Cell Cycle, and Protein Kinase Pathways in DU145 Human Prostate Cancer Cells." <u>Mol. Cancer Ther.</u> 1: 1059-1066 (2002)	
		KASSEROLLER et al., "Treatment of secondary lymphedema of the arm with physical decongestive therapy of sodium selenite: a review." <u>Am J Ther.</u> 7(4): 273-9 (2000)	
		LEUNG et al., "Effect of L-Buthionine Sulfoximine on the Radiation Response of Human Renal Carcinoma Cell Lines." <u>Cancer.</u> 71: 2276-85 (1993)	
		MACKEY et al., "bcl-2/bzx Ratio as a Predictive Marker for Therapeutic Response to Radiotherapy in Patients with Prostate Cancer." <u>Urology.</u> 52(6): 1085-1090 (1998)	
		MEDINA et al., "Current Ideas on Selenium as a Chemopreventive Agent." <u>Pathol Immunopathol Res.</u> 7: 187-199 (1988);	
		MENTER et al., "Selenium Effects on Prostate Cell Growth." <u>Cancer Epid. Biomarkers. Prev.</u> , 9:1171-1182 (2000)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/

PTO/SB/08b (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	10/576,568
		Filing Date	January 3, 2007
		First Named Inventor	KNOX, SUSAN J.
		Art Unit	1645
Sheet 5 of 6	Examiner Name		
		Attorney Docket Number	STAN-333

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MICKE et al., "Selenium in the Treatment of Radiation-Associated Secondary Lymphedema." <u>Int. J. Radiation Oncology Biol. Phys.</u> 56(1):44-49 (2003)	
		MILNER et al., "Inhibitory Effects of Selenium on the Growth of L1210 Leukemic Cells." <u>Cancer Res.</u> 41: 1652-1656 (1981)	
		MILNER et al., "Effect of selenium on virally induced and transplantable tumor models." <u>Fed Proc.</u> 44: 2568-2572 (1985)	
		OHKAWA et al., "The effects of co-administration of selenium and <i>cis</i> -platin (CDDP) on CDDP-induced toxicity and antitumor activity." <u>Br. J. Cancer</u> , 58(1):38-41 (1988)	
		PERRY et al., "Glutathione Levels and Variability in Breast Tumors and Normal Tissue." <u>Cancer</u> . 72(3): 783-787 (1993)	
		SHAMBERGER et al., "Selenium Distribution and Human Cancer Mortality." <u>CRC Crit Rev Clin Sci</u> . 2: 211-219 (1971)	
		SHEN et al., "Superoxide Radical-Initiated Apoptotic Signalling Pathway in Selenite-Treated HEPG ₂ Cells: Mitochondria Serve as the Main Target." <u>Free Radic. Biol. Med.</u> 30(1): 9-21 (2001)	
		SHEN et al., "Dual Role of Glutathione in Selenite-Induced Oxidative Stress and Apoptosis in Human Hepatoma Cells." <u>Free Radic. Biol. Med.</u> 28(7):1115-1124 (2000)	
		SHEN et al., "Sodium Selenite-Induced Oxidative Stress and Apoptosis in Human Hematoma HepG ₂ Cells." <u>Int. J. Cancer</u> . 81: 820-828 (1999)	
		SPALLHOLZ. "Selenium and the Prevention of Cancer." <u>Bulletin of Sellenium-Tellurium Dev. Ass'n</u> May (2001)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/576,568	
			Filing Date	January 3, 2007	
			First Named Inventor	KNOX, SUSAN J.	
			Art Unit	1645	
			Examiner Name		
Sheet	6	of	6	Attorney Docket Number	STAN-333

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		THOMPSON et al., "Comparison of the effects of an organic and an inorganic form of selenium on a mammary carcinoma cell line." <u>Carcinogenesis</u> 15(2): 183-186 (1994)	
		WACHOWICZ et al., "Selenium compounds in the environment: their effect on human health" <u>Cell. Mol. Biol. Lett.</u> 6:375-381 (2001)	
		WATRACH et al., "Inhibition of Human Breast Cancer Cells by Selenium." <u>Cancer Lett.</u> 25: 41-47 (1984)	
		WATRACH et al., "Effect of Selenium on Growth Rate of Canine Mammary Carcinoma Cells in Athymic Nude Mice." <u>Cancer Lett.</u> 15: 137-143 (1982)	
		WEBBER et al., "Inhibitory Effects of Selenium on the Growth of DU-145 Human Prostate Carcinoma Cells In Vitro." <u>Biochem. Biophys. Res. Commun.</u> , 130(2):603-609 (1985)	
		YUAN et al., "Coordinate Alterations in the Expression of BRCA1, BRCA2, p300 and Rad51 in Response to Genotoxic and Other Stresses in Human Prostate Cancer Cells." <u>The Prostate</u> 40: 37-49 (1999)	
		ZHONG et al., "Redox-mediated Effects of Selenium on Apoptosis and Cell Cycle in the LNCaP Human Prostate Cancer Cell Line." <u>Cancer Res.</u> 61: 7071-7078 (2001)	
		ZHOU et al., "DNA Damage-mediated Apoptosis Induced by Selenium Compounds." <u>J. Biol. Chem.</u> 278(32): 29532-29537 (2003)	

Examiner Signature	/Frank Choi/	Date Considered	12/21/2008
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /FC/